Search bioRxiv⌕ Search

Biology subjects

Li, X.-y.

Publications and source records attributed to Li, X.-y..

3 recordsLinked to original sources

The Zelda interactome reveals diverse co-factors essential for the Drosophila zygotic genome activation

Zelda (Zld) is the master pioneer transcription factor essential for zygotic genome activation (ZGA) during the Drosophila maternal-to-zygotic transition (MZT). While Zld is known to promote chromatin accessibility at early enhancers and possess multiple conserved functional domains, the specific protein complexes it recruits to execute its functions remain poorly defined. Using an optimized immunoprecipitation and mass spectrometry (IP-MS) pipeline in Stage 4-5 embryos, we identified a diverse Zld interactome. This repertoire includes the coactivators dCBP and Fsh (the Drosophila Brd4 ortholog), subunits of major nucleosome remodeling complexes(e.g. PBAP/BAP, NURF, FACT), RNA polymerase II (RNAPII), the corepressor Smrter (Smr), and the Tousled-like kinase (Tlk). We confirmed the enrichment of ten key factors at Zld-bound regions using CUT&RUN. Notably, our results demonstrate that RNAPII associates not only with Zld-bound promoters but also with distal Zld-binding sites. This finding, which contrasts with previous ChIP-based studies, suggests that Zld facilitates transcription by actively scaffolding or pre-recruiting the transcriptional machinery at enhancers. Functional analyses revealed that dCBP and Fsh are required for Zld-mediated activation, while RNAi knockdown of smr led to the broad derepression of Zld-target genes, suggesting that Smr modulates Zld activity to prevent premature expression. Finally, we show that Tlk, a kinase typically associated with DNA replication, directly interacts with a specific Zld domain in vitro and co-localizes with Zld in vivo. This suggests a novel mechanism by which Zld may coordinate transcriptional activation with the rapid mitotic cycles of early embryogenesis. Collectively, our findings provide a comprehensive map of the Zld interactome and reveal how a pioneer factor integrates diverse chromatin and transcriptional regulators to orchestrate zygotic genome activation.

genomics↗

The expression of IL-35 in the prophase of liver failure and its preliminary exploration for the mechanism of immunoregulation by IL-35 and glucocorticoids

Background and AimsTo determine appropriate dosages for mice models in liver failure prophase and explore IL-35 and cytokine levels. Also, investigate changes in Treg/ Th17 ratio, IL-35, and IL-17 in patients with HBV-induced liver failure before and after treatment. MethodsWe induced liver failure in mice with different doses of concanavalin and assessed severity through serum biochemistry and pathology. Mice were divided into control, model, IL-35 plasmid, anti-IL-35, and dexamethasone groups. IL-35 and IL-17 expressions in liver tissue were evaluated via immunohistochemistry, fluorescence staining, and ELISA. Treg/Th17 ratio and IL-35 and IL-17 levels in peripheral blood of patients were measured using flow cytometry and ELISA, compared to 22 healthy individuals. ResultsThe optimal dose for the liver failure model was 20 g/ kg concanavalin. The IL-35 plasmid and dexamethasone groups showed significantly lower serum TBil, ALT, AST, IL-4, IL-17, TNF- , and liver histopathology scores compared to the model group, while the anti-IL-35 group showed higher levels (P<0. 05). In HBV-PLF patients, TBil, ALT, and AST significantly decreased, and PTA increased after glucocorticoid treatment (P<0. 05). Treg/ Th17 ratio was lower in HBV-PLF patients compared to the healthy group (P<0. 05), with higher IL-35 and IL-17 levels (P<0. 05). Post-treatment, Treg increased and Th17 decreased significantly; IL-17 and Treg/ Th17 ratios increased, while IL-35 decreased (P<0.05). IL-35 positively correlated with the Treg/Th17 ratio. Conclusions 20 g/ kg concanavalin proper dose for mice model. IL-35 may protect in liver failure. Glucocorticoids help maintain immune balance, prevent failure, increase ratios and IL-35 in HBV-PLF patients, and IL-35 related to Treg/Th17 balance.

immunology↗

Alteration in Gut Microbiome and Intestinal Barrier Function caused by Efavirenz versus Dolutegravir Treatments in Mice

Dolutegravir (DTG) is replacing efavirenz (EFV) as first-line antiretroviral therapy because of its better tolerance. However, DTG cause similar, but milder, gastrointestinal and neurological side effects as EFV does. We speculated that impaired gut barrier function contributes to their side effects. For this purpose, the mice were intragastrically administered EFV, DTG, or vehicle for 60 consecutive days. The plasma levels of FITC-dextran were determined to evaluate gut barrier integrity. Colonic contents were collected for 16S rRNA sequencing. Adipose, liver, ileum, and colon tissues were collected for pathological examination, and intestinal zona occludens-1 (ZO-1) immunofluorescence staining and goblet cell staining were performed. We found that EFV significantly retarded body weight gain, decreased glucose uptake, and caused lipodystrophy and hepatocyte necrosis. EFV also decreased species richness of gut microbiota, increased Verrucomicrobia and Proteobacteria, and decreased Patescibacteria and Cyanobacteria. Moreover, it caused crypt damage, goblet cell loss, reduced ZO-1 expression, impaired gut barrier function, and suppressed expressions of Pdha1 and Ndufv1. Interestingly, DTG impaired barrier function similar to EFV, but the impairment was milder. DTC also inhibited MPC1, MPC2, and Pdha1 expression. Our results suggest a link between abnormal energy metabolism, impaired gut barrier integrity and side effects of EFV and DTG.

immunology↗